Strattera withdrawal
Pro Research Analysisby 
Searched over 200M research papers for "strattera withdrawal"
Understanding Strattera Withdrawal: Key Insights
Introduction to Strattera (Atomoxetine)
Strattera, known generically as atomoxetine, is a selective norepinephrine reuptake inhibitor used primarily to treat attention deficit hyperactivity disorder (ADHD) in both adults and children. Unlike stimulant medications, atomoxetine is a nonstimulant and is not classified as a controlled substance, making it a valuable option for patients at risk of substance abuse or those who prefer nonstimulant treatments.
Efficacy and Tolerability of Atomoxetine
Clinical trials have demonstrated that atomoxetine is effective in reducing ADHD symptoms. In two large, well-controlled 10-week trials, adults with ADHD showed significant improvements in symptoms when treated with atomoxetine compared to placebo. The improvements were measured using various scales, including the Conners' Adult ADHD Rating Scale (CAARS) and the Clinician Global Impression of Severity Scale.
Atomoxetine was generally well tolerated, although some patients experienced adverse events such as dry mouth, insomnia, nausea, decreased appetite, and dizziness. Withdrawal rates due to adverse events were higher in atomoxetine-treated patients compared to those receiving a placebo.
Withdrawal and Adverse Effects
While atomoxetine is generally well tolerated, withdrawal from the medication can lead to the re-emergence of ADHD symptoms. Additionally, some patients may experience withdrawal symptoms such as mood swings, irritability, and fatigue. It is important to taper off the medication gradually under medical supervision to minimize these effects.
Severe Liver Injury and Atomoxetine
There have been reports of severe liver injury associated with atomoxetine use. In one case, a child developed acute hepatitis with no other identifiable cause, which resolved completely after discontinuing the medication. Another case involved a child with type 1 autoimmune hepatitis, who improved after stopping atomoxetine and receiving immunosuppressive therapy. These cases highlight the importance of monitoring liver function during treatment and being vigilant for signs of liver injury.
Conclusion
Atomoxetine (Strattera) is an effective nonstimulant medication for treating ADHD in adults and children. While it is generally well tolerated, it is crucial to be aware of potential withdrawal symptoms and the risk of severe liver injury. Gradual tapering and close monitoring can help manage these risks effectively. Atomoxetine remains a valuable treatment option, particularly for patients who prefer nonstimulant medications or are at risk of substance abuse.
Sources and full results
Most relevant research papers on this topic